These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 32687855)

  • 1. Utilization of CRISPR/Cas9 gene editing in cellular therapies for lymphoid malignancies.
    Mehravar M; Roshandel E; Salimi M; Chegeni R; Gholizadeh M; Mohammadi MH; Hajifathali A
    Immunol Lett; 2020 Oct; 226():71-82. PubMed ID: 32687855
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CRISPR-Cas9 genome editing for cancer immunotherapy: opportunities and challenges.
    Chen M; Xu J; Zhou Y; Zhang S; Zhu D
    Brief Funct Genomics; 2020 May; 19(3):183-190. PubMed ID: 31788683
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic status and the prospect of CRISPR/Cas9 gene editing in multiple myeloma.
    Hong L; Zhang C; Jiang Y; Liu H; Huang H; Guo D
    Future Oncol; 2020 Jun; 16(16):1125-1136. PubMed ID: 32338048
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Challenges of in vitro genome editing with CRISPR/Cas9 and possible solutions: A review.
    Ebrahimi V; Hashemi A
    Gene; 2020 Aug; 753():144813. PubMed ID: 32470504
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The application of CRISPR-Cas9 genome editing tool in cancer immunotherapy.
    Wu HY; Cao CY
    Brief Funct Genomics; 2019 Mar; 18(2):129-132. PubMed ID: 29579146
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Harnessing CRISPR/Cas9 technology in cardiovascular disease.
    Rezaei H; Khadempar S; Farahani N; Hosseingholi EZ; Hayat SMG; Sathyapalan T; Sahebkar AH
    Trends Cardiovasc Med; 2020 Feb; 30(2):93-101. PubMed ID: 30935726
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CRISPR/Cas9-based epigenome editing: An overview of dCas9-based tools with special emphasis on off-target activity.
    Tadić V; Josipović G; Zoldoš V; Vojta A
    Methods; 2019 Jul; 164-165():109-119. PubMed ID: 31071448
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Applications and advances of CRISPR-Cas9 in cancer immunotherapy.
    Xia AL; He QF; Wang JC; Zhu J; Sha YQ; Sun B; Lu XJ
    J Med Genet; 2019 Jan; 56(1):4-9. PubMed ID: 29970486
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetical engineering for NK and T cell immunotherapy with CRISPR/Cas9 technology: Implications and challenges.
    Zhi L; Su X; Yin M; Zhang Z; Lu H; Niu Z; Guo C; Zhu W; Zhang X
    Cell Immunol; 2021 Nov; 369():104436. PubMed ID: 34500148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Delivery strategies of the CRISPR-Cas9 gene-editing system for therapeutic applications.
    Liu C; Zhang L; Liu H; Cheng K
    J Control Release; 2017 Nov; 266():17-26. PubMed ID: 28911805
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genome Editing in CAR-T Cells Using CRISPR/Cas9 Technology.
    Andreu-Saumell I; Rodriguez-Garcia A; Guedan S
    Methods Mol Biol; 2024; 2748():151-165. PubMed ID: 38070114
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Applying switchable Cas9 variants to in vivo gene editing for therapeutic applications.
    Mills EM; Barlow VL; Luk LYP; Tsai YH
    Cell Biol Toxicol; 2020 Feb; 36(1):17-29. PubMed ID: 31418127
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CRISPR/Cas9 and CAR-T cell, collaboration of two revolutionary technologies in cancer immunotherapy, an instruction for successful cancer treatment.
    Mollanoori H; Shahraki H; Rahmati Y; Teimourian S
    Hum Immunol; 2018 Dec; 79(12):876-882. PubMed ID: 30261221
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gene Therapy with CRISPR/Cas9 Coming to Age for HIV Cure.
    Soriano V
    AIDS Rev; 2017; 19(3):167-172. PubMed ID: 29019352
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CRISPR/Cas9 Platforms for Genome Editing in Plants: Developments and Applications.
    Ma X; Zhu Q; Chen Y; Liu YG
    Mol Plant; 2016 Jul; 9(7):961-74. PubMed ID: 27108381
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent Advances in CRISPR/Cas9-Mediated Genome Editing in
    Muramoto T; Iriki H; Watanabe J; Kawata T
    Cells; 2019 Jan; 8(1):. PubMed ID: 30642074
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CRISPR/Cas9 system: a powerful technology for in vivo and ex vivo gene therapy.
    Zhang X; Wang L; Liu M; Li D
    Sci China Life Sci; 2017 May; 60(5):468-475. PubMed ID: 28534255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Coassembly of nucleus-targeting gold nanoclusters with CRISPR/Cas9 for simultaneous bioimaging and therapeutic genome editing.
    Tao Y; Yi K; Hu H; Shao D; Li M
    J Mater Chem B; 2021 Jan; 9(1):94-100. PubMed ID: 33220661
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CRISPR/Cas9-mediated genome editing: From basic research to translational medicine.
    Jacinto FV; Link W; Ferreira BI
    J Cell Mol Med; 2020 Apr; 24(7):3766-3778. PubMed ID: 32096600
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genome editing: A perspective on the application of CRISPR/Cas9 to study human diseases (Review).
    Rodríguez-Rodríguez DR; Ramírez-Solís R; Garza-Elizondo MA; Garza-Rodríguez ML; Barrera-Saldaña HA
    Int J Mol Med; 2019 Apr; 43(4):1559-1574. PubMed ID: 30816503
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.